Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Autoimmune disease

Calcium channel N-type; calcium channel P/Q-type

Cell-based and mouse studies identified an agonist of N- and P/Q-type calcium channels that could help treat Lambert-Eaton myasthenic syndrome. In cultured cells expressing N- or P/Q-type calcium channels, the roscovitine derivative GV-58 increased calcium conductance compared with vehicle control. In a mouse model for Lambert-Eaton myasthenic syndrome, GV-58 increased transmitter release from neuromuscular junctions compared with vehicle. Next steps include optimizing the compound and conducting tests in additional models for neuromuscular disorders.

SciBX 6(28); doi:10.1038/scibx.2013.713
Published online July 25, 2013

Patent application filed; available for licensing

Tarr, T.B. et al. J. Neurosci.; published online June 19, 2013;
doi:10.1523/JNEUROSCI.4629-12.2013
Contact: Stephen D. Meriney, University of Pittsburgh, Pittsburgh, Pa.
e-mail:
meriney@pitt.edu
Contact: Peter Wipf, same affiliation as above
e-mail:
pwipf@pitt.edu